Table 2.
Comparison of HIV viral load values at the different time points between the HBcAb-positive patients living with HIV (PLWH) and HBcAb-negative PLWH groups.
| Patients Characteristics | HBcAb-Positive (n = 58) |
HBcAb-Negative (n = 108) |
p-Value | |
|---|---|---|---|---|
| Sex ratio M:F (%F *) | 46:12 (20.7%) | 82:26 (24.1%) | 0.62 | |
| Age, years | 55 (51–61) | 49 (37–57) | 0.0007 | |
| Calendar year of HIV diagnosis ** | 2002 (1999–2010) | 2008 (2006–2014) | 0.0001 | |
| Nadir CD4+ cell/mmc ** | 251 (145–341) | 316 (201–446) | 0.047 | |
| History of therapeutic failure * | 12 (20.7%) | 12 (11.1%) | 0.26 | |
| Pre-2DR switch triple ART composition * | 0.023 | |||
| Two NRTIs + PI | 31 (53.4%) | 34 (31.5%) | ||
| Two NRTIs + NNRTI | 12 (20.7%) | 26 (24.1%) | ||
| Two NRTIs + INI | 12 (20.7%) | 44 (40.7%) | ||
| Other | 3 (5.2%) | 4 (3.7%) | ||
| Reason for switch | 0.44 | |||
| Therapeutic failure pre-switch | 1 (1.7%) | 2 (1.85) | ||
| Toxicity | 4 (6.8%) | 10 (9.2%) | ||
| Drug interaction | 7 (12.1%) | 17 (15.7%) | ||
| Pill burden | 3 (5.2%) | 9 (8.3%) | ||
| Pre-emptive switch | 43 (74.1%) | 70 (64.8%) | ||
| 2DR composition * | 0.51 | |||
| 3TC + PI | 24 (41.4%) | 35 (32.4%) | ||
| 3TC + DTG | 34 (58.6%) | 73 (67.6%) | ||
| CD4+ cell/mmc at 2DR switch ** | 660 (552–845) | 703 (543–894) | 0.58 | |
| HIV RNA 24 months pre-2DR switch * | 0.53 | |||
| pts <20 copies/mL | 47 (81%) | 83 (76.8%) | ||
| pts <20 copies/mL target detected | 11 (19%) | 25 (23.2%) | ||
| HIV RNA 12 months pre-2DR switch * | 0.31 | |||
| pts <20 copies/mL | 44 (75.9%) | 89 (82.4%) | ||
| pts <20 copies/mL target detected | 14 (24.1%) | 19 (17.6%) | ||
| HIV RNA at 2DR switch * | 0.87 | |||
| pts <20 copies/mL | 43 (74.1%) | 83 (76.8%) | ||
| pts <20 copies/mL target detected | 13 (22.4%) | 23 (21.3%) | ||
| Not available | 2 (1.8%) | 2 (3.4%) | ||
| HIV RNA 6 months post-2DR switch* | 0.047 | |||
| pts <20 copies/mL | 40 (69%) | 89 (82.4%) | ||
| pts <20 copies/mL target detected | 18 (31%) | 19 (17.6%) | ||
| HIV RNA 12 months post-2DR switch *†† | 0.001 | |||
| pts <20 copies/mL | 18 (34%) | 56 (61.5%) | ||
| pts <20 copies/mL target detected | 18 (34%) | 25 (27.5%) | ||
| pts detectable >20 copies/mL | 17 (32%) | 10 (11%) | ||
| CD4+ cell/mmc at 24 months post 2DR switch *‡ | 698 (592–932) | 771 (669–947) | 0.64 | |
| HIV RNA 24 months post-2DR switch *‡ | 0.003 | |||
| pts <20 copies/mL | 12 (26%) | 41 (51.9%) | ||
| pts <20 copies/mL target detected | 17 (37%) | 27 (34.2%) | ||
| pts detectable >20 copies/mL | 17 (37%) | 11 (13.9%) | ||
* Number (%); ** Median (IQR); 3TC: lamivudine; NRTIs: nucleoside reverse transcriptase inhibitors; NNRTI: nonnucleoside reverse transcriptase inhibitors; PI: protease inhibitors; DTG: dolutegravir; 2DR: two-drug antiretroviral therapy; pts: patients; HBcAb-positive: patients with antibodies against hepatitis B c antigen. †† Data available for 144 pts; ‡ Data available for 125 pts; bold numbers if p-value < 0.05.